Arovella Therapeutics Ltd has released a press release.
Market Update
Filed with ASX ·
On 6ix: 6ix.com/news/market-update-238
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Suspension from Official Quotation
- Anagrelide Cancer Patent For Japan
- SUDA Signs Additional Licence With Mitsubishi Tanabe
- Half Yearly Report and Accounts
- SANOFI and SUDA Entered Into A Feasibility Agreement
Later from Arovella Therapeutics
- Entitlement Offer To Raise Approximately $3.56 Million
- Prospectus For Entitlement Offer
- TGA Approval Granted For ZolpiMist
- Appendix 4C - quarterly
- Anagrelide Cancer Patent For Australia
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics